TRAW Traws Pharma Inc.
Price (delayed)
$2.32
Market cap
$11.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$35.21
Enterprise value
-$9.57M
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has
Highlights
Traws Pharma's net income has plunged by 189% YoY but it has soared by 61% from the previous quarter
The quick ratio has surged by 185% since the previous quarter but it has declined by 18% year-on-year
Key stats
What are the main financial stats of TRAW
Market
Valuations
Earnings
Shares outstanding
5.07M
Market cap
$11.77M
Enterprise value
-$9.57M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
15.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-42.33
Revenue
$226,000
Gross profit
$226,000
Operating income
-$142.37M
Net income
-$54.67M
EBIT
-$54.67M
EBITDA
-$54.66M
Free cash flow
-$29.79M
Per share
Balance sheet
Liquidity
EPS
-$35.21
EPS diluted
-$35.21
Free cash flow per share
-$19.19
Book value per share
-$10.45
Revenue per share
$0.15
TBVPS
$16.08
Total assets
$24.96M
Total liabilities
$56.59M
Debt
$0
Equity
-$31.63M
Working capital
$13.42M
Debt to equity
0
Current ratio
2.16
Quick ratio
1.85
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-24,186.7%
Gross margin
100%
Net margin
-24,192%
Operating margin
-62,997.3%
Return on assets
-309.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-407.1%
Return on sales
-24,192%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRAW stock price
How has the Traws Pharma stock price performed over time
Intraday
8.41%
1 week
-8.3%
1 month
-29.91%
1 year
-90.68%
YTD
-73.87%
QTD
0.87%
Financial performance
How have Traws Pharma's revenue and profit performed over time
Revenue
$226,000
Gross profit
$226,000
Operating income
-$142.37M
Net income
-$54.67M
Gross margin
100%
Net margin
-24,192%
Traws Pharma's net income has plunged by 189% YoY but it has soared by 61% from the previous quarter
The net margin has plunged by 189% YoY but it has soared by 61% from the previous quarter
Growth
What is Traws Pharma's growth rate over time
Valuation
What is Traws Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
15.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-42.33
The EPS has soared by 75% from the previous quarter but it has plunged by 56% YoY
The price to sales (P/S) is 93% lower than the 5-year quarterly average of 205.7 and 74% lower than the last 4 quarters average of 57.5
Efficiency
How efficient is Traws Pharma business performance
The ROS has plunged by 189% YoY but it has soared by 61% from the previous quarter
TRAW's return on assets has surged by 62% since the previous quarter
Dividends
What is TRAW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRAW.
Financial health
How did Traws Pharma financials performed over time
TRAW's total assets is 56% smaller than its total liabilities
The quick ratio has surged by 185% since the previous quarter but it has declined by 18% year-on-year
TRAW's total assets has surged by 179% since the previous quarter and by 10% year-on-year
The debt is 100% more than the equity
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.